Building a leadership team with global and local experience and expertise to enable rapid execution across our broad range of therapeutic strategies
Durham, North Carolina When Beijing, August 22, 2022 /PRNewswire/ — Brii Biosciences Limited (“Brii Bio” or the “Company”, Stock Code: 2137.HK) develops innovative treatments for diseases with significant unmet medical need and great public health burden It announced today that it is a multinational company that develops laws.Schedule of Eleanor (Ellie) de GrootPh.D., Chief Technology Officer and aleksandar sukubanMD, Head of Central Nervous System (CNS) Disease Treatment Area.
“Both Ellee and Aleksandar are seasoned biotechnology leaders with impressive credentials and entrepreneurial histories of leading drug development and manufacturing initiatives in their respective functional areas. We are thrilled to welcome them to the Brii Bio team as we continue to advance our pipeline, on behalf of patients facing significant health challenges around the world.” Shihiro, Ph.D., Chairman and CEO of Brii Bio. “With experience spanning all stages of pharmaceutical manufacturing, Ellee is a key figure in our leadership team in implementing our wide range of therapies. Aleksandar’s deep expertise will prioritize advances in leading US treatment programs in postpartum depression, major depressive disorder and anxiety disorders.”
Eleanor (Ellie) de GrootPhD, Chief Technology Officer
Dr. de Groot has over 20 years of experience leading streamlined and broad global operations across growing biotechnology companies, from early to late stage clinical development and commercial scale manufacturing. Dr. de Groot has held key leadership roles during his career at Alaunos Therapeutics, most recently as Vice President of Operations, overseeing the development of new cell therapy programs and leading clinical manufacturing, quality and process development. Did. Additionally, during his tenure at Helsinn Therapeutics, Dr. de Groot assumed multiple roles of increasing responsibility within his CMC management team, including global regulatory engagement, technology transfer, and leading business with his partners around the world. led preparations for the commercialization of the drug, including cooperation with Dr. de Groot holds a Ph.D.and MSc in Chemical Engineering Stanford Universitywith a Bachelor of Science in Chemical Engineering Massachusetts Institute of Technology (MIT) and a Master of Business Administration Rice University.
“We believe Brii Bio’s diverse pipeline of promising therapeutic candidates shows great potential to address some of the greatest public health challenges of our time, and we support its ongoing product development.” and I would like to contribute my expertise to create a sustainable long-term growth strategy…in-house.” Ellie de GrootPh.D., Chief Technology Officer at Brii Bio.
aleksandar sukubanMD, Head of CNS Therapeutic Area
Dr. Skuban brings over 25 years of global pharmaceutical research and development experience and broad medical and scientific expertise, including leading over 30 studies across therapeutic areas, from early stage proof of concept to positive regulatory results. , brings a track record of business leadership to Brii Bio. Focusing on central nervous system diseases. Previously, he served as Senior Vice President of Clinical Development at Better Therapeutics, where he developed research strategies to enable rapid development of new indications for prescription digital therapeutics. Prior to that, he served as Executive Director, He Medical, leading clinical development of Alexion’s new ophthalmic therapeutic area. At Otsuka, Dr. Skuban’s tenure includes oversight of a variety of clinical portfolios, most notably his FDA approval of Breexpiprazole (REXULTI) for major depressive disorder and schizophrenia. led. Dr. Skuban has also held numerous clinical development director roles at Merck and Sanofi-Aventis. He holds a doctorate in medicine from the Semmelweis Medical School. Budapest, Hungary attended the medical faculty of the University of Novi Sad, Novi Sad, Yugoslavia (Serbia).
“I am inspired by the meaningful patient-centric approach Brii Bio has cultivated in the early stages of clinical planning. We look forward to ensuring that we are well-positioned for the future of mental illness, based on a fundamental understanding of healthcare and patient preferences and needs.” aleksandar sukubanMD, Head of Central Nervous System Therapeutic Area at Brii Bio.
About Brii Bio
Brii Biosciences Limited (“Brii Bio”, stock code: 2137.HK) is a Singapore-based biotechnology company. China When usa Treatment of critical infections such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multidrug-resistant (MDR) or extensively drug-resistant (XDR) Gram-negative infections, and other illnesses We are working to advance the law. As a central nervous system (CNS) disease, it carries a significant public health burden. China and around the world. For more information, please visit www.briibio.com.
Source Brii Biosciences Limited